Inhaled drug developer Aradigm has announced the appointment of Robert A. Reed as VP, Regulatory (CMC) and Quality. Reed was most recently Senior VP of CMC and Technical Operations at Celsion Corporation and has also previously held positions at XenoPort and Merck.
Aradigm President and CEO Igor Gonda commented, “We are delighted that Dr. Reed has joined our team at this critical juncture when our investigational drug Pulmaquin is in global Phase 3 clinical trials for the management of patients with non-cystic fibrosis bronchiectasis. His rich experience in late stage product development and approval, as well the commercial scale manufacturing of respiratory and liposomal therapeutics, is a particularly important addition to our expertise.”
The company announced the initiation of a second Phase 3 trial for Pulmaquin for the treatment of lung infections in patients with non-CF bronchiectasis in June 2014. The product received Fast Track designation for that indication from the FDA in September 2014.
Read the Aradigm press release.
